Servier signs $1.55B upfront deal for Edgewise's muscular dystrophy assets
Servier will pick up the muscular dystrophy business from Edgewise Therapeutics for $1.55 billion upfront, giving the French pharma company access to an experimental neuromuscular medicine that could have pivotal data by year's end. The ...
June 1, 2026 08:31 AM EDT DealsPharma Servier signs $1.55B upfront deal for Edgewise's muscular dystrophy assets Kyle LaHucik Biotech Correspondent Servier will pick up the muscular dystrophy business from Edgewise Therapeutics for $1.55 billion upfront, giving the French pharma company access to an experimental neuromuscular … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that